Pacific Edge : Lotan et al Commentary on Novitas LCD DL39365

Commentary on Novitas LCD

Yair Lotan1, Daniel A Barocas2, Sam S Chang2, Siamak Daneshmand3, Badrinath Konety4, Joshua J Meeks5, Sima Porten6, Jay D. Raman7, Charles J Rosser8, Kristen R Scarpato2, Wade J Sexton9, John P Sfakianos10, Neal D Shore11,Robert S Svatek 12

1University of Texas Southwestern, Dallas, Texas.

1. Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
2. Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
   4Allina Health Cancer Institute, Minneapolis, MN and University of Minnesota, Minneapolis, MN

1. Department of Urology and Biochemistry, Feinberg School of Medicine, Northwestern University, Chicago, IL
2. Department of Urology, University of San Francisco, California
3. Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania.
   8Samuel Oschin Cancer Center, Cedars-SinaiMedical Center, Los Angeles, CA, USA 9Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL

10 Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.

11Carolina Urologic Research Center, Myrtle Beach, SC, USA

12 Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Conflicts of Interest: Yair Lotan: Consultant

Nanorobotics, C2I genomics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Nucleix, Ambu, Seattle Genetics, Hitachi, Ferring Research, verity pharmaceutics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Xcures, BMS, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc, CG oncology, Uroviu, On target lab

Daniel Barocas: Pacific Edge, Ambu, Lantheus, Pfizer, On target labs

Sam Chang: Consultant

Astellas, Merck, Janssen, Pfizer, Virtuoso Surgical, Photocure, Tu Therapeutics, Nonagen, Pacific Edge , Urogen, Prokarium, Valar Science

Siamak Daneshmand

Consultant for: Janssen, Ferring, Photocure, Taris, Spectrum, Pacific Edge, BMS, Sesen, Protara, Pfizer, CG Oncology

Badrinath Konety: Consultant for Pacific Edge, Astrin Biosciences, Asieris Pharmaceuticals, Convergent Genomics, Illumina, Ferring Pharmaceuticals, Styx Biotechnology, Geneverify.

Joshua Meeks: Consultant: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen,

Prokarium, Imvax, Pfizer, Seagen/Astellas, Research Funding: VHA, NIH, DoD,

Compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday,

Clinical Trials: SWOG, Genentech, Merck, AstraZeneca, Incyte

Sima Porten: Research with, KDx, Nonagen and Signatera, Consultant with Pacific Edge.

Jay Raman: Education Chair for American Urological Association; Investment interest in United Medical Systems; Ongoing research with MDxHealth, Pacific Edge, Urogen Pharma, Steba Biotech

Charles Rosser: Executive team for Nonagen Bioscience Corp.

Kristen Scarpato: Photocure, CxBladder

John P Sfakianos: Natera and pacific edge.

Wade J. Sexton: Pacific Edge, Urogen Pharmaceuticals

Neal Shore: Arquer,Astra Zeneca, Aura biosciences, Diacarta, Ferring, Janssen, MDxHealth, Merck, Pacific Edge, Photocure, Protara, Roche

Robert Svatek: Consultant CG Oncology and Verity Pharma

The role of biomarkers (aka, markers) in detecting and managing cancer is an evolving field. It is crucial to develop biomarkers robustly that mirror drug development in the pharmaceutical industry. The goal for markers should be to provide a clear benefit in managing patients that is additive to both clinical and laboratory information. Markers should be developed in phases, with initial assay development and validation followed by clinical studies to evaluate the marker's performance characteristics in assessing specific clinical conditions (e.g., sensitivity, specificity, predictive value) and ability to improve a clinically meaningful outcome. Ultimately, economic validation is also

warranted, especially as we move forward with value-based healthcare. Trials should focus on answering specific clinical questions and thereby demonstrate the incremental value of the marker in predicting the benefit of a treatment or detection of a defined disease state. Additionally, the benefits of the marker need to be balanced by any harmful interpretation that can occur from false positive and false negative results, which could lead to patient anxiety, unnecessary costs, and as well as potentially incorrect clinical decision making predicated on test result.

While clinical utility is arguably the most important parameter to judge the value of a marker in managing a patient, acceptable reimbursement is a critical component for the viability of a marker. A marker with evidence-based utility which is not reimbursed will thus render it unavailable for patients and clinicians thereby forfeiting a valuable tool(s) in clinical decision making. Novitas Solutions, Inc. (Novitas) provides administrative services for government-sponsoredhealthcare programs and serves as a Part A/B Medicare Administrative Contractor (MAC) under multiple contracts for the Centers for Medicare and Medicaid Services (CMS). As a MAC, Novitas serves as a single point-of-contact entity processing Medicare Part A and B claims from hospitals and other institutional providers, physicians and practitioners. Novitas serves the Medicare Program in Jurisdiction L, which encompasses Delaware, New Jersey, Pennsylvania, Maryland, as well as the District of Columbia, and Jurisdiction H which includes Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma and Texas. The recent release of a draft local coverage determination (LCD Genetic Testing for Oncology) by Novitas proposes a fundamental change to the criteria Novitas would use to determine coverage for molecular diagnostic tests.

In the draft LCD, Novitas proposed a new external review model for coverage determined only by including or excluding the tests or biomarkers in one of a limited number of external databases and published guidelines (references to ClinGen, NCCN, and OncoKB). Before the draft LCD, the established determination process was for MACs to determine coverage and reimbursement through a product-specific internal review of the published literature. Such a change in the LCD would drastically impact urine-based tumor marker use and accessibility since Novitas proposes to severely limit coverage for a variety of markers.

While this draft specifically focused on a few urine markers (among other molecular tests) including the Cxbladder urinary tests (detect, triage, and monitor urine-based markers) and UroVysion fluorescence in situ hybridization (FISH), this approval process change could have a profound ripple effect with significant deleterious impact on other current and future urine marker tests. Hence, it is of paramount importance to consider the implication of such a ruling for additional biomarker accessibility, the merits of the decision and, most importantly, its implication for optimized clinical care.

When considering urine marker development for bladder cancer, there has been considerable effort to identify candidate markers or panels of markers to improve the evaluation of at-cancer risk patients, especially those with hematuria, and to enhance

surveillance of bladder cancer specifically.1-3 It is important to delineate the specific clinical scenario which in turn can significantly impact the type of marker needed. A comprehensive marker evaluation may not always capture the specific value in answering a clinical question. For example, a marker used to help determine which patients with hematuria should undergo further evaluation would optimally have a high negative predictive value (NPV) so that cancer is not missed rather than a high positive predictive value (PPV) which limits evaluation to only a small percentage of patients. The rationale for the aforementioned approach being that if patients meet the criteria for microhematuria with current recommendations to perform cystoscopy in most cases, then excluding patients at extremely low risk for cancer could be an excellent way to improve compliance (and decrease costs) with evaluation while limiting unnecessary procedures (cystoscopy and imaging).2,4,5

Furthermore, any positive marker result (whether true or false) would be followed up with a cystoscopy, thereby avoiding incremental testing beyond current standard of care. In other clinical scenarios, such as patients with abnormal cystoscopy or cytology that is atypical but not conclusive for cancer, a marker with a high PPV would be valuable since the goal would be to biopsy those patients who are likely to have cancer but avoid unnecessary surgery in patients who may have inflammation or other benign changes. The American Urologic Association (AUA)/ Society of Urologic Oncology (SUO) guidelines for non-muscle invasive bladder cancer (NMIBC) already state that a clinician may use biomarkers to assess response to intravesical BCG (UroVysion® FISH) and adjudicate equivocal cytology (UroVysion® FISH and ImmunoCyt™).6 A recent publication also found that CxBladder Monitor could adjudicate patients with atypical cytology or equivocal cystoscopy7, showing up to 35% of patients can avoid unnecessary further procedures.

There are several concerns with the types of criticisms raised by Novitas in the draft LCD (Genetic Testing for Oncology). The first is based on limited published guidelines (references to ClinGen, NCCN, and OncoKB). The NCCN guidelines are focused on patients with a known diagnosis of cancer, and their only statement on pre-diagnosisis a recommendation for all patients with hematuria to undergo cystoscopy. As such, they do not focus on evaluating hematuria or managing unique scenarios like atypical cystoscopy or cytology, which urologists routinely must manage. The AUA has developed guidelines for managing hematuria in conjunction with the Society of Urodynamics Female Pelvic Medicine and Urogenital Reconstruction (SUFU)5.

Similarly, the AUA and SUO developed guidelines for the management of NMIBC6. These guidelines include standardized methodology and evaluation of all available data with recommendations based on robust levels of evidence. They evaluate the role of urine markers and other tests for detecting and managing bladder cancer. It would be inappropriate for Novitas to ignore the recommendations of these widely accepted guidelines in making decision regarding reimbursement/coverage.

Novitas did not specify why it was excluding the Urovysion FISH assay, which has been FDA-approved for more than two decades and whose use has been supported by the AUA guidelines to assess response to intravesical BCG and adjudicate equivocal cytology (as noted above). They had specific concerns regarding the Cxbladder line of tests. While Novitas focused on these markers, many criticisms could be applied to other urine markers.

One comment focused on the fact that the tested patient population included a strong bias towards male patients of European ancestry and that the Cxbladder tests have not been adequately investigated in the context of the Medicare population. The focus on male patients is inherent in all studies related to bladder cancer because there are more than three times as many bladder cancer cases in men relative to women. In 2023, of the 82,290 newly diagnosed bladder cancer patients, there were 62,420 men versus 19,870 women8. There is a significantly higher rate9 of bladder cancer in whites relative to non-white populations. The average annual age-standardizedincidence in the US was 0.49, 0.61, 0.4, and 0.46 relative to whites for black, American Indian, and Alaska Native, Asian American and Pacific Islander, and Hispanic, respectively. Moreover, it is challenging to enroll many minority patients in large bladder cancer trials since they represent a smaller percentage of the prevalence population and have a lower relative cancer rate.

It is also unclear why Novitas asserted that Cxbladder tests were not vetted in the context of Medicare patients since the average age of bladder cancer patients is over

70. In the study evaluating CxBladder Monitor, 82% of the patients were over 6010 years of age. Thus, it seems this marker is particularly focused on the Medicare population, as is the case for most markers used for bladder cancer surveillance. Another area of concern raised by Novitas pertained to issues related to false positive tests. There is no question that most urine markers suffer from a low PPV, impacting their clinical performance, interpreting Clinical scenarios where a patient undergoes a surveillance cystoscopy with no demonstrable tumor albeit with a positive urine marker presents a clinical conundrum. In such cases, whether the white light cystoscopy "missed" cancer or the marker is falsely positive is a dilemma. The use of enhanced cystoscopy has illustrated the fact that white light cystoscopy can miss some papillary tumors and carcinoma in situ, which may result in a positive marker11. Multiple papers have been published on "anticipatory" positive results for many different markers12-14, finding that patients with a positive marker are more likely to recur during an extended follow up than patients with a negative marker. The important question is the role of the marker in this setting. For example, the PPV of markers is much higher if there are equivocal findings on cystoscopy which resulted in the AUA guidelines supporting the use of markers in that setting15. In the case of the Cxbladder monitor test, the design of the test was to focus on NPV and not PPV. Since the marker was designed to optimize sensitivity, it is not surprising that the specificity is lower. If one tries to avoid cystoscopy in some patients, the high NPV will facilitate reducing the number of cystoscopies. Similarly, an attempt to reduce cystoscopy in patients with low-risk clinical features with microscopic hematuria would also benefit from a marker with high NPV. There is still a need for ongoing trials to support this latter use. A randomized trial